Enrollment in the Phase 1b/2 NEXICART-2 trial of CAR-T NXC-201 is complete with 45 patients.
The company plans a randomized Phase 3 study in newly diagnosed AL amyloidosis.
Quarterly loss and expense trends
Immix Biopharma posted a net loss of USD 11.56 million for the quarter ended June 30, 2026, widening from USD 6.62 million a year earlier.
General and administrative expense climbed to USD 7.12 million from USD 2.75 million, driven by higher compensation and professional fees tied to capital-raising.
Research and development expense rose to USD 5.33 million from USD 3.97 million, on higher clinical-trial and licensing costs; USD 0.5 million of CIRM reimbursements offset R&D.
Interest income increased to USD 913,663 from USD 104,056 as the company maintained higher balances in money market funds and U.S. Treasuries.
IMMX•
